Delving into the Latest Updates on Interferon alfa-2b(Vektor Medika) with Synapse

Overview

Basic Info

Drug Type

Interferons, Biosimilar

Synonyms

Reaferon-EC-Lipint, Reaferon-ES-Lipint, Reaferon-EU-Lipint

Target

IFNAR

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers

Therapeutic Areas

Infectious Diseases

Active Indication

Virus Diseases

Inactive Indication-

Originator Organization

Vektor Medika

Active Organization

Vektor Medika

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 26333714

The sequence is quoted from: *****

The efficacy of the therapeutic, prophylactic and urgent prophylactic schemes for the use of Reaferon-ES lipint, a liposomal human recombinant alpha-interferon for oral use, was studied on mice infected with the avian influenza virus. Strain A/Chicken/Kurgan /05/2005 (subtype H5N1) of the avian influenza virus showed high virulence with respect to mice ICR. Theoretically-based calculations allowed to design an optimal therapeutic and prophylactic dose of the drug for the mice (1000 units/animal). It was observed that only after prophylactic use of Reaferon-ES lipint it was effective in protection of the mice infected with 10 LD50 of the avian influenza virus (A/Chicken/Kurgan/05/2005, H5N1). The protection coefficient was 0.35. Under such conditions the drug efficacy was comparable with that of Tamiflu. Therefore, Reaferon-ES lipint could be recommended for prophylaxis of the infection due not only to the season strains of the influenza virus, but also to the strains of the avian influenza virus.

01 Jul 2001·Der OphthalmologeQ4 · MEDICINE

Schwerer beidseitiger Sehverlust bei malignem Melanom der Haut

Q4 · MEDICINE

Article

Author: T. Bogenrieder ; D. Spiegel ; C. P. Lohmann ; G. Kroher ; B. Gabler ; J. Preuner

100 Deals associated with Interferon alfa-2b(Vektor Medika)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02745	Interferon alfa-2b(Vektor Medika)	L03AB05	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Virus Diseases	RU	Vektor Medika	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


E 1697 (ASCO2011)	Phase 3	Melanoma	1,150	Interferon alfa-2b 20 MU/m2/day for 4 weeks	(vzwkbqfgvw) = zoubirrxls plizxtijyn (okfeynmpxw, 5.1 - 9.0)	Negative	20 May 2011
				interferon alfa-2b (Observation)	(vzwkbqfgvw) = yroceypvtt plizxtijyn (okfeynmpxw, 5.3 - 9.8)